{"id":"W2993267366","doi":"10.1016/j.ahj.2019.08.012","title":"Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program","year":2019,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"British Microcirculation Society; Merck Sharp and Dohme; Johnson and Johnson; H. Lundbeck A/S; Actelion Pharmaceuticals; Pfizer; Covidien; Daiichi-Sankyo; Bundesministerium für Bildung und Forschung; Abbott Laboratories; National Institute for Health and Care Research; Boehringer Ingelheim; AstraZeneca; Allergan; National Institutes of Health; Cilag; Medtronic; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Bayer Vital; Bristol-Myers Squibb; Bayer HealthCare; Sanofi; European Commission; St. Jude Medical","keywords":"Medicine; Dabigatran; Atrial fibrillation; Incidence (geometry); Myocardial infarction; Stroke (engine); Cohort; Clinical Practice; Internal medicine; Warfarin; Prospective cohort study; Emergency medicine; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006458347,0.0007888656,0.001605266,0.0007223626,0.0005583588,0.002001086,0.001185092,0.001192089,0.001315121],"category_scores_gemma":[0.009163135,0.0004194375,0.003142304,0.0009801829,0.0006932321,0.002057218,0.00164812,0.001880558,0.0006659047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001376535,"about_ca_system_score_gemma":0.00285794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004571405,"about_ca_topic_score_gemma":0.008053808,"domain_scores_codex":[0.9963085,0.001551902,0.0003213161,0.0005970702,0.000711807,0.0005094518],"domain_scores_gemma":[0.9921058,0.001633639,0.002951649,0.001172632,0.001025497,0.001110745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07530309,0.003515061,0.8826041,0.0002496621,0.004827736,0.000200397,0.0003481127,0.001740015,0.0008427686,0.0002972255,0.006371215,0.02370065],"study_design_scores_gemma":[0.01576648,0.01329103,0.9632072,0.0001089749,0.002789738,0.0002558135,0.0003570973,0.001436261,0.000666702,0.0002652729,0.001773378,0.0000821589],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914683,0.0006234203,0.0002261529,0.0003940119,0.00002809101,0.0002290299,0.005530021,0.00003657355,0.001464346],"genre_scores_gemma":[0.9856331,0.0003927236,0.0003621032,0.0004602829,0.00006213493,0.0002501968,0.01208604,0.00002702015,0.000726422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006458347,"threshold_uncertainty_score":0.03415537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04080461857395852,"score_gpt":0.3642790742672046,"score_spread":0.3234744556932461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}